多西他赛联合奥沙利铂及卡培他滨治疗进展期胃癌的疗效
及安全性评估——单中心非对照Ⅱ期临床研究
刘瑾;马韬;叶正宝;张俊;朱正纲
【期刊名称】《中华胃肠外科杂志》 【年(卷),期】2010(013)003
【摘要】目的 评价多西他赛联合奥沙利铂及卡培他滨方案(DOX方案)治疗进展期胃癌的临床疗效和不良反应.方法 采用单中心非对照Ⅱ期临床研究,进展期胃癌患者30例入组.DOX方案为:多西他赛75 mg/m~2,第1天,静脉滴注2 h;奥沙利铂130 mg/m~2,第1天,静脉滴注2 h:卡培他滨1000 mg/m~2,2次/d,口服,1～14 d;每21 d为1周期.至少2周期后评价疗效及不良反应.结果 入组30例患者均根据RECIST标准评估疗效,完全缓解1例,部分缓解2例,稳定25例,进展2例;有效率为10.0%(3/30),疾病控制率为93.3%(28/30).中位随访时间261 d,全组患者中位无进展生存期197 d,中位总生存期466 d.不良反应:18例(60.0%)发生Ⅲ~Ⅳ度白细胞减少,13例(43.3%)发生Ⅲ~Ⅳ度中性粒细胞减少,9例(30.0%)出现粒细胞减少性发热,8例(26.7%)发生Ⅲ~Ⅳ度乏力.结论 DOX方案治疗进展期胃癌疗效较好,有一定的耐受性,值得进一步扩大样本量开展后续研究.%Objective To assess the efficacy and safety of docetaxel plus oxaliplatin and capecitabine (DOX) in the treatment of advanced gastric adenocarcinoma. Methods A total of 30 patients were recruited to receive DOX regimen (docetaxel 75 mg/m~2 day 1, oxaliplatin 130 mg/m~2 day 1, and capecitabine 1000 mg/m~2 bid d1-14, repeated every 3 weeks). Only those who completed at least 2 cycles were
assessed. Results The number of patients with complete response, partial response, stable disease and progressive disease were 1, 2, 25 and 2, respectively. The objective response rate was 10.0%(3/30) and the disease control rate was 93.3%(28/30). After a median follow-up of 261 days, the median progression free survival and overall survival time were 197 days and 466 days, respectively. The most common grade Ⅲ to Ⅵ toxicity was hematologic toxicity. The percentage of patients with grade Ⅲ to Ⅵ leucopenia, neutropenia and febrile neutropenia were 60.0%, 43.3% and 30.0%, respectively. The most common grade Ⅲ to Ⅵ non-hematologic toxicitywas fatigue, nausea, vomiting, anorexia, diarrhea, and hand-foot syndrome. Conclusions DOX regimen demonstrates promising efficacy in the treatment of advanced gastric adenocarcinoma. The associated toxicity can be well tolerated and controlled. Large scale clinical trial is necessary to obtain further evidence.
【总页数】4页(177-180)
【关键词】胃肿瘤;化学疗法;多西他赛;奥沙利铂;卡培他滨;治疗效果;安全性 【作者】刘瑾;马韬;叶正宝;张俊;朱正纲
【作者单位】200025,上海交通大学医学院附属瑞金医院外科,上海消化外科研究所;200025,上海交通大学医学院附属瑞金医院外科,上海消化外科研究所;200025,上海交通大学医学院附属瑞金医院外科,上海消化外科研究所;200025,上海交通大学医学院附属肿瘤放化疗科;200025,上海交通大学医学
院附属瑞金医院外科,上海消化外科研究所 【正文语种】中文 【中图分类】 【文献来源】
https://www.zhangqiaokeyan.com/academic-journal-cn_chinese-journal-gastrointestinal-surgery_thesis/0201234347419.html 【相关文献】
1.奥沙利铂联合卡培他滨治疗进展期胃癌的临床疗效评估 [J], 何广思; 蒋宗惠 2.替吉奥联合多西他赛与卡培他滨联合多西他赛治疗进展期胃癌的疗效对比观察 [J], 刘广国; 邹文蓉; 赵清梅; 陈娟
3.卡培他滨或替吉奥联合奥沙利铂方案治疗进展期胃癌的疗效及安全性 [J], 万一元; 惠红霞; 王晓炜; 吴健; 孙苏安
4.奥沙利铂联合卡培他滨一线治疗进展期胃癌的临床疗效观察 [J], 董宁宁; 王明玉; 张琼; 刘志芳
5.卡培他滨联合奥沙利铂治疗进展期老年胃癌患者的疗效和安全性 [J], 张雪刚; 柯贤胜
以上内容为文献基本信息，获取文献全文请下载
多西他赛联合奥沙利铂及卡培他滨治疗进展期胃癌的疗效及安全性评
